Cargando…
Immune camouflage: Relevance to vaccines and human immunology
High strain sequence variability, interference with innate immune mechanisms, and epitope deletion are all examples of strategies that pathogens have evolved to subvert host defenses. To this list we would add another strategy: immune camouflage. Pathogens whose epitope sequences are cross-conserved...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514035/ https://www.ncbi.nlm.nih.gov/pubmed/25483703 http://dx.doi.org/10.4161/hv.36134 |
_version_ | 1782382734825488384 |
---|---|
author | De Groot, Anne S Moise, Lenny Liu, Rui Gutierrez, Andres H Tassone, Ryan Bailey-Kellogg, Chris Martin, William |
author_facet | De Groot, Anne S Moise, Lenny Liu, Rui Gutierrez, Andres H Tassone, Ryan Bailey-Kellogg, Chris Martin, William |
author_sort | De Groot, Anne S |
collection | PubMed |
description | High strain sequence variability, interference with innate immune mechanisms, and epitope deletion are all examples of strategies that pathogens have evolved to subvert host defenses. To this list we would add another strategy: immune camouflage. Pathogens whose epitope sequences are cross-conserved with multiple human proteins at the TCR-facing residues may be exploiting “ignorance and tolerance," which are mechanisms by which mature T cells avoid immune responses to self-antigens. By adopting amino acid configurations that may be recognized by autologous regulatory T cells, pathogens may be actively suppressing protective immunity. Using the new JanusMatrix TCR-homology-mapping tool, we have identified several such ‘camouflaged’ tolerizing epitopes that are present in the viral genomes of pathogens such as emerging H7N9 influenza. Thus in addition to the overall low number of T helper epitopes that is present in H7 hemaglutinin (as described previously, see http://dx.doi.org/10.4161/hv.24939), the presence of such tolerizing epitopes in H7N9 could explain why, in recent vaccine trials, whole H7N9-HA was poorly immunogenic and associated with low seroconversion rates (see http://dx.doi.org/10.4161/hv.28135). In this commentary, we provide an overview of the immunoinformatics process leading to the discovery of tolerizing epitopes in pathogen genomic sequences, provide a brief summary of laboratory data that validates the discovery, and point the way forward. Removal of viral, bacterial and parasite tolerizing epitopes may permit researchers to develop more effective vaccines and immunotherapeutics in the future. |
format | Online Article Text |
id | pubmed-4514035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-45140352015-11-01 Immune camouflage: Relevance to vaccines and human immunology De Groot, Anne S Moise, Lenny Liu, Rui Gutierrez, Andres H Tassone, Ryan Bailey-Kellogg, Chris Martin, William Hum Vaccin Immunother NOVEL VACCINES/Commentaries High strain sequence variability, interference with innate immune mechanisms, and epitope deletion are all examples of strategies that pathogens have evolved to subvert host defenses. To this list we would add another strategy: immune camouflage. Pathogens whose epitope sequences are cross-conserved with multiple human proteins at the TCR-facing residues may be exploiting “ignorance and tolerance," which are mechanisms by which mature T cells avoid immune responses to self-antigens. By adopting amino acid configurations that may be recognized by autologous regulatory T cells, pathogens may be actively suppressing protective immunity. Using the new JanusMatrix TCR-homology-mapping tool, we have identified several such ‘camouflaged’ tolerizing epitopes that are present in the viral genomes of pathogens such as emerging H7N9 influenza. Thus in addition to the overall low number of T helper epitopes that is present in H7 hemaglutinin (as described previously, see http://dx.doi.org/10.4161/hv.24939), the presence of such tolerizing epitopes in H7N9 could explain why, in recent vaccine trials, whole H7N9-HA was poorly immunogenic and associated with low seroconversion rates (see http://dx.doi.org/10.4161/hv.28135). In this commentary, we provide an overview of the immunoinformatics process leading to the discovery of tolerizing epitopes in pathogen genomic sequences, provide a brief summary of laboratory data that validates the discovery, and point the way forward. Removal of viral, bacterial and parasite tolerizing epitopes may permit researchers to develop more effective vaccines and immunotherapeutics in the future. Taylor & Francis 2014-11-01 /pmc/articles/PMC4514035/ /pubmed/25483703 http://dx.doi.org/10.4161/hv.36134 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | NOVEL VACCINES/Commentaries De Groot, Anne S Moise, Lenny Liu, Rui Gutierrez, Andres H Tassone, Ryan Bailey-Kellogg, Chris Martin, William Immune camouflage: Relevance to vaccines and human immunology |
title | Immune camouflage: Relevance to vaccines and human immunology |
title_full | Immune camouflage: Relevance to vaccines and human immunology |
title_fullStr | Immune camouflage: Relevance to vaccines and human immunology |
title_full_unstemmed | Immune camouflage: Relevance to vaccines and human immunology |
title_short | Immune camouflage: Relevance to vaccines and human immunology |
title_sort | immune camouflage: relevance to vaccines and human immunology |
topic | NOVEL VACCINES/Commentaries |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514035/ https://www.ncbi.nlm.nih.gov/pubmed/25483703 http://dx.doi.org/10.4161/hv.36134 |
work_keys_str_mv | AT degrootannes immunecamouflagerelevancetovaccinesandhumanimmunology AT moiselenny immunecamouflagerelevancetovaccinesandhumanimmunology AT liurui immunecamouflagerelevancetovaccinesandhumanimmunology AT gutierrezandresh immunecamouflagerelevancetovaccinesandhumanimmunology AT tassoneryan immunecamouflagerelevancetovaccinesandhumanimmunology AT baileykelloggchris immunecamouflagerelevancetovaccinesandhumanimmunology AT martinwilliam immunecamouflagerelevancetovaccinesandhumanimmunology |